Healius Ltd
HLS: XASX (AUS)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| — | — | — | LOCK|>^>gw^p |
Healius Earnings: Subdued Referrals Weigh on Result, but Margins Poised to Expand on Cost Savings
Healius' interim 2026 underlying EBIT improved to AUD 8 million versus an AUD 3 million loss last year. Revenue rose a solid 4% despite weak general practitioner referrals. Healius is guiding to roughly AUD 48 million in EBIT for the full year. Shares fell 7%.
